Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study-Reference-Cited by-同舟云学术

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study

Published:2023-06 Issue: Volume:Volume 16 Page:625-636
ISSN:1178-6965
Container-title:Journal of Asthma and Allergy
language:en
Short-container-title:JAA

Author:

Su Nan,Zhi Lili,Liu Fengxia,Wang Yongsheng,Zhang Qingling,Liu Xiansheng^ORCID,Wang Xueyan,Hao Guodong,Zhang Xiuqin,Hu Qiang^ORCID,Ligueros-Saylan Monica,Uddin Alkaz,Yang Jing,Liang Tiantian,Ding Liju,Li Runqin,Wang Chen

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy

Reference24 articles.

1. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

2. Global Initiative for Asthma. Global strategy for asthma management and prevention revised 2014; 2014. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf. Accessed July 28, 2022.

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

4. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study

5. Global Asthma Network. The global asthma report 2018; 2018. Available from: www.globalasthmanetwork.org. Accessed July 12, 2022.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract;Meditsinskiy sovet = Medical Council;2023-11-16

2. Asthma Phenotypes in the Era of Personalized Medicine;Journal of Clinical Medicine;2023-09-26

3. Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life;Journal of Personalized Medicine;2023-06-29